https://www.scmp.com/rss/511051/feed As the biopharmaceutical sector undergoes transformation, Samsung Bioepis leads the field in the development of biosimilar products, to provide affordable healthcare options. en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com With the prolonged impact of Covid-19 across the health care sector and throughout the globe, everyone has been affected in some way. The pandemic has tested our economies and our health care systems, as well as our everyday lives. The unprecedented impact of Covid-19 on health care systems has changed the landscape of the pharmaceutical industry. The need for cost-effective treatments to ease the financial burden is greater than ever, and limited financial resources must be allocated to... https://www.scmp.com/presented/business/topics/innovations-health-care-access/article/3153946/passion-health-how-samsung?utm_source=rss_feed https://www.scmp.com/presented/business/topics/innovations-health-care-access/article/3153946/passion-health-how-samsung?utm_source=rss_feed Thu, 28 Oct 2021 06:56:13 +0000 Samsung Bioepis is expanding its presence in the biopharmaceutical sector in what it says is a move to improve access to health care. The South Korean company, which is the biopharmaceutical arm of the Samsung Group, plans to use its technological know-how to create products and services that contribute to a better global society. Samsung Bioepis was established in 2012 to provide affordable health care to patients, especially those who had limited options previously due to the high costs of... https://www.scmp.com/presented/lifestyle/health/topics/innovations-health-care-access/article/3153680/samsung-bioepis?utm_source=rss_feed https://www.scmp.com/presented/lifestyle/health/topics/innovations-health-care-access/article/3153680/samsung-bioepis?utm_source=rss_feed Tue, 26 Oct 2021 06:57:22 +0000